Cancer Biomarkers

Scope & Guideline

Connecting Researchers to Cutting-Edge Cancer Insights.

Introduction

Welcome to your portal for understanding Cancer Biomarkers, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1574-0153
PublisherIOS PRESS
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 2005 to 2024
AbbreviationCANCER BIOMARK / Cancer Biomark.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressNIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS

Aims and Scopes

Cancer Biomarkers focuses on the exploration and identification of biomarkers that can aid in the diagnosis, prognosis, and treatment of various cancers. The journal emphasizes the integration of molecular biology, genomics, and bioinformatics to discover new potential biomarkers and therapeutic targets.
  1. Biomarker Discovery and Validation:
    The journal extensively publishes research aimed at discovering novel biomarkers that can be used for early detection, diagnosis, and prognosis of different cancer types.
  2. Molecular Mechanisms of Cancer:
    Research articles often focus on elucidating the molecular pathways and mechanisms through which identified biomarkers influence cancer progression and response to therapies.
  3. Genomic and Epigenomic Studies:
    A significant focus is placed on genomic and epigenomic alterations in cancer, including DNA methylation patterns and gene expression profiles that correlate with clinical outcomes.
  4. Machine Learning and Bioinformatics:
    The journal supports the application of machine learning and bioinformatics tools to analyze complex datasets and identify biomarkers with clinical relevance.
  5. Immune Biomarkers and Microenvironment:
    Research exploring the role of immune-related biomarkers and the tumor microenvironment in cancer progression and treatment response is a key area of focus.
Recent publications in Cancer Biomarkers indicate a dynamic evolution in research themes, with several emerging areas gaining traction. These trends reflect advancements in technology and a growing understanding of cancer biology, leading to innovative approaches in biomarker research.
  1. Long Non-Coding RNAs (lncRNAs):
    Research on lncRNAs is rapidly increasing, highlighting their potential roles as biomarkers for various cancers, particularly in regulating gene expression and cancer progression.
  2. Immune Checkpoint Inhibitors:
    The exploration of biomarkers related to immune checkpoint inhibitors is trending, reflecting the rise of immunotherapy as a cornerstone in cancer treatment.
  3. Multi-Omics Approaches:
    There is a growing trend towards multi-omics studies, integrating genomic, transcriptomic, proteomic, and metabolomic data to provide comprehensive insights into cancer biology and biomarker discovery.
  4. Artificial Intelligence in Biomarker Discovery:
    The use of AI and machine learning algorithms to analyze complex datasets and improve biomarker identification and validation is an emerging theme, indicating a shift towards data-driven research methodologies.
  5. Tumor Microenvironment Studies:
    Research focusing on the tumor microenvironment and its impact on cancer progression and therapy response is gaining prominence, emphasizing the interplay between cancer cells and their surrounding environment.

Declining or Waning

While Cancer Biomarkers continues to thrive in various research areas, certain themes have shown a noticeable decline in publication frequency over recent years. This waning interest may reflect shifts in research priorities or advancements in technology that have rendered previous approaches less prominent.
  1. Traditional Tumor Markers:
    Research focusing on conventional tumor markers such as CEA or CA 19-9 appears to be declining as novel biomarkers and more sophisticated molecular techniques gain prominence.
  2. Single Biomarker Studies:
    There has been a shift away from studies focusing solely on single biomarkers, as the field moves towards multi-biomarker panels and integrative approaches that consider the complexity of cancer biology.
  3. Invasive Diagnostic Techniques:
    Research on invasive diagnostic methods is waning in favor of non-invasive liquid biopsy techniques that utilize circulating biomarkers for cancer detection and monitoring.
  4. Chemotherapy Response Predictors:
    The exploration of predictive biomarkers specifically for chemotherapy response has decreased, likely due to a broader focus on immunotherapy and targeted therapies.
  5. Non-specific Biomarkers:
    Interest in non-specific biomarkers that lack clear associations with particular cancer types or outcomes has diminished as the field emphasizes more precise and context-specific biomarker identification.

Similar Journals

Journal of Cancer Metastasis and Treatment

Empowering researchers with vital oncology knowledge.
Publisher: OAE PUBLISHING INCISSN: 2394-4722Frequency: 1 issue/year

Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.

Biomarker Research

Pioneering research for transformative diagnostics and therapeutics.
Publisher: BMCISSN: Frequency: 1 issue/year

Biomarker Research is a leading open access journal published by BMC, dedicated to advancing the field of biomarker discovery and clinical application. Since its inception in 2013, this journal has become a crucial resource for researchers and professionals in biochemistry, clinical biochemistry, and molecular medicine, achieving a prestigious Q1 ranking in each category in 2023. With an E-ISSN of 2050-7771, it maintains a strong reputation for disseminating high-quality research and innovative findings that contribute to the understanding of disease mechanisms and the development of novel diagnostics and therapeutics. The journal is accessible to a global audience, ensuring that vital research is freely available to promote collaboration and accelerate scientific progress. Operating out of the United Kingdom, Biomarker Research plays a significant role in addressing some of the most pressing challenges in medical research, making it an essential resource for academics, clinicians, and industry professionals alike.

Annual Review of Cancer Biology

Exploring the Complexities of Cancer Science
Publisher: ANNUAL REVIEWSISSN: 2472-3428Frequency: 1 issue/year

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Pioneering discoveries that shape the future of oncology.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Molecular Therapy Oncolytics

Advancing Oncological Science for Global Impact
Publisher: CELL PRESSISSN: 2372-7705Frequency: 1 issue/year

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Pioneering Research in Molecular Genetics
Publisher: ELSEVIERISSN: 1386-1964Frequency: 12 issues/year

MUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS is a premier peer-reviewed journal published by Elsevier, dedicated to advancing the understanding of mutagenesis and its broader implications in genetics, health, and molecular biology. With an impressive converged publication history from 1964 to 2024, this journal provides a vital platform for the dissemination of high-quality research findings, contributing significantly to the field's knowledge base. Indexed in Scopus, it holds a Category Quartile ranking of Q3 in Genetics and Q2 in Health, Toxicology, and Mutagenesis, further underscoring its relevance and stature. Access options are available, catering to a diverse audience of researchers, professionals, and students eager to stay informed on the latest developments in mutagenesis research. By bridging experimental studies and theoretical frameworks, the journal plays a crucial role in exploring the fundamental mechanisms underlying genetic mutations and their effects on human health and the environment.

Cancer Genomics & Proteomics

Pioneering discoveries in cancer genomics and proteomics.
Publisher: INT INST ANTICANCER RESEARCHISSN: 1109-6535Frequency: 6 issues/year

Cancer Genomics & Proteomics is a pivotal journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of cancer genomics and proteomics. Established in 2004 and running until 2024, this journal provides a vital platform for the dissemination of high-quality research that explores genetic and protein interactions in cancer, thereby fostering innovations in diagnostics and therapeutics. The journal boasts a commendable Q2 ranking in Biochemistry and Genetics and is recognized in the Q3 tier for its contributions to Cancer Research and Molecular Biology, reflecting its growing impact in these dynamic fields. Operating out of Greece, it engages a diverse audience, including researchers, clinicians, and students, by sharing significant findings and methodological advancements in the realm of cancer studies. While currently not an open-access publication, Cancer Genomics & Proteomics remains committed to enriching scientific dialogue and collaboration with its insightful articles and reviews.

Cancer Communications

Connecting Researchers, Practitioners, and Patients in Oncology
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

Molecular and Clinical Oncology

Uncovering the molecular secrets of oncology.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Cancer Immunology Research

Fostering Innovation in Cancer Immunotherapy
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2326-6066Frequency: 12 issues/year

Cancer Immunology Research is a leading journal dedicated to the rapidly evolving field of cancer immunology, published by the American Association for Cancer Research. Established in 2013, this prestigious journal has quickly made a significant impact in its domain, achieving a 2023 Q1 ranking in both Cancer Research and Immunology. With an impressive Scopus rank of 24 out of 230 in cancer research and 28 out of 236 in immunology, it occupies a valuable position for researchers, professionals, and students engaged in cutting-edge cancer studies. Although it does not offer open access, the journal is committed to disseminating high-quality, peer-reviewed research that advances our understanding of the immune system’s role in cancer. The journal's objectives include fostering innovative studies, enhancing collaboration across disciplines, and promoting the translation of research findings into clinical applications, making it a vital resource for anyone invested in cancer therapy and immunological research.